JP2010522242A5 - - Google Patents

Download PDF

Info

Publication number
JP2010522242A5
JP2010522242A5 JP2010501112A JP2010501112A JP2010522242A5 JP 2010522242 A5 JP2010522242 A5 JP 2010522242A5 JP 2010501112 A JP2010501112 A JP 2010501112A JP 2010501112 A JP2010501112 A JP 2010501112A JP 2010522242 A5 JP2010522242 A5 JP 2010522242A5
Authority
JP
Japan
Prior art keywords
disease
tachyarrhythmia
crohn
pain
bowel syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010501112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010522242A (ja
JP5361857B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/057730 external-priority patent/WO2008118758A1/en
Publication of JP2010522242A publication Critical patent/JP2010522242A/ja
Publication of JP2010522242A5 publication Critical patent/JP2010522242A5/ja
Application granted granted Critical
Publication of JP5361857B2 publication Critical patent/JP5361857B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010501112A 2007-03-23 2008-03-20 イオンチャネルの阻害剤 Expired - Fee Related JP5361857B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US89673507P 2007-03-23 2007-03-23
US60/896,735 2007-03-23
US3532408P 2008-03-10 2008-03-10
US61/035,324 2008-03-10
PCT/US2008/057730 WO2008118758A1 (en) 2007-03-23 2008-03-20 Inhibitors of ion channels

Publications (3)

Publication Number Publication Date
JP2010522242A JP2010522242A (ja) 2010-07-01
JP2010522242A5 true JP2010522242A5 (enExample) 2011-04-21
JP5361857B2 JP5361857B2 (ja) 2013-12-04

Family

ID=39788940

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010501112A Expired - Fee Related JP5361857B2 (ja) 2007-03-23 2008-03-20 イオンチャネルの阻害剤

Country Status (14)

Country Link
US (2) US8357711B2 (enExample)
EP (1) EP1995241B1 (enExample)
JP (1) JP5361857B2 (enExample)
AR (1) AR065824A1 (enExample)
AT (1) ATE461177T1 (enExample)
CA (1) CA2681572C (enExample)
CL (1) CL2008000835A1 (enExample)
DE (1) DE602008000809D1 (enExample)
ES (1) ES2340640T3 (enExample)
PA (1) PA8773501A1 (enExample)
PE (1) PE20090237A1 (enExample)
TW (1) TW200845969A (enExample)
UY (1) UY30978A1 (enExample)
WO (1) WO2008118758A1 (enExample)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009023272A1 (en) 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
PT2197849E (pt) * 2007-10-09 2013-04-23 Merck Patent Gmbh Derivados de n-(pirazole-3-il)-benzamida como ativadores de glucoquinase
GB0815947D0 (en) * 2008-09-02 2008-10-08 Univ Dundee Compounds
WO2010033824A1 (en) * 2008-09-19 2010-03-25 Icagen, Inc. Sulfonamide derivatives as inhibitors of ion channels
WO2010035166A1 (en) * 2008-09-23 2010-04-01 Pfizer Limited Benzamide derivatives
JP2012506376A (ja) * 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 2,5−二置換モルホリンオレキシン受容体アンタゴニスト
HRP20150355T1 (hr) * 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
CN102427810A (zh) * 2009-05-01 2012-04-25 拉夸里亚创药株式会社 作为trpm8拮抗剂的氨磺酰基苯甲酸衍生物
JP5685203B2 (ja) 2009-05-29 2015-03-18 ラクオリア創薬株式会社 カルシウムチャネル遮断薬またはナトリウムチャネル遮断薬としてのアリール置換カルボキサミド誘導体
BR112012009574A2 (pt) * 2009-10-22 2019-09-24 Univ Vanderbilt potencializador alostérico de mglura, composições, e métodos de tratamento de disfunção neurológica
US9051296B2 (en) 2009-11-16 2015-06-09 Raqualia Pharma Inc. Aryl carboxamide derivatives as TTX-S blockers
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
WO2011104649A1 (en) 2010-02-25 2011-09-01 Pfizer Limited Peptide analogues
EA201201289A1 (ru) * 2010-03-16 2013-08-30 Мерк Патент Гмбх Морфолинилхиназолины
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2590957B1 (en) 2010-07-09 2014-11-12 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
US9145407B2 (en) 2010-07-09 2015-09-29 Pfizer Limited Sulfonamide compounds
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
WO2012007877A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
WO2012007883A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2813708C (en) * 2010-10-18 2019-09-17 Raqualia Pharma Inc. Arylamide derivatives as ttx-s blockers
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2681200A4 (en) 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
AP2013007159A0 (en) 2011-04-05 2013-10-31 Pfizer Ltd Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase
US8957025B2 (en) 2011-07-13 2015-02-17 Pfizer Inc. Enkephalin analogues
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
US9079878B2 (en) 2011-10-26 2015-07-14 Pfizer Limited (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
EP2771325B1 (en) 2011-10-28 2017-06-28 Inhibitaxin Limited Pyridazine derivatives useful in therapy
US9630929B2 (en) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
JP6067031B2 (ja) 2012-01-04 2017-01-25 ファイザー・リミテッドPfizer Limited N−アミノスルホニルベンズアミド
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
US9701658B2 (en) 2012-04-25 2017-07-11 Raqualia Pharma Inc. Amide derivatives as TTX-S blockers
KR101719893B1 (ko) 2012-05-22 2017-03-24 제넨테크, 인크. N-치환된 벤즈아미드 및 통증의 치료에서 이들의 용도
JP6309519B2 (ja) 2012-07-06 2018-04-11 ジェネンテック, インコーポレイテッド N置換ベンズアミド及びその使用方法
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
EP2903989A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
JP2015531393A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドPfizer Limited トロポミオシン関連キナーゼ阻害剤
ES2828503T3 (es) 2012-10-15 2021-05-26 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
WO2014153037A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Substituted triazolopyridines and methods of use thereof
EP2970156B1 (en) 2013-03-15 2018-07-25 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
WO2014139144A1 (en) * 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
EP2988748A1 (en) * 2013-04-23 2016-03-02 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
AU2014356967A1 (en) 2013-11-27 2016-07-07 Genentech, Inc. Substituted benzamides and methods of use thereof
EP3083602A1 (en) 2013-12-20 2016-10-26 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CA2950393A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
JP6491679B2 (ja) 2014-06-12 2019-03-27 ファイザー・リミテッドPfizer Limited Gabaa受容体活性のモジュレーターとしてのイミダゾピリダジン誘導体
JP2017525677A (ja) 2014-07-07 2017-09-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
MA42118A (fr) 2015-05-22 2018-03-28 Genentech Inc Benzamides substitués et leurs méthodes d'utilisation
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX386501B (es) 2015-09-28 2025-03-19 Genentech Inc Compuestos terapeuticos y sus metodos de uso
EP3380466A1 (en) 2015-11-25 2018-10-03 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
JP2018536677A (ja) 2015-12-10 2018-12-13 ファイザー・リミテッドPfizer Limited てんかんおよび疼痛の治療において使用するための、GABA受容体モジュレーターとしての式(I)の4−(ビフェン−3−イル)−1H−ピラゾロ[3,4−c]ピリダジン誘導体
JP2019502688A (ja) * 2015-12-18 2019-01-31 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 電位作動型ナトリウムチャネルにおいて選択的活性を有するジアミノ−アルキルアミノ結合アリールスルホンアミド化合物
US10766858B2 (en) 2016-03-30 2020-09-08 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2019532077A (ja) 2016-10-17 2019-11-07 ジェネンテック, インコーポレイテッド 治療用化合物及びその使用方法
US11046683B2 (en) 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
WO2018132550A1 (en) 2017-01-11 2018-07-19 The General Hospital Corporation Voltage gated sodium channel imaging agents
CN110546148A (zh) 2017-03-24 2019-12-06 基因泰克公司 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物
CN110740915B (zh) * 2017-06-27 2022-11-15 本田技研工业株式会社 行驶控制系统以及车辆的控制方法
MX2020002147A (es) * 2017-08-25 2022-10-03 The Board Of Supervisors Of Louisiana State Univ And Agricultural And Mechanical College Composiciones útiles para la mejora del dolor.
AR114263A1 (es) 2018-02-26 2020-08-12 Genentech Inc Compuestos terapéuticos y métodos para utilizarlos
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
CN108752274B (zh) * 2018-07-25 2022-03-29 遂成药业股份有限公司 一种5-异喹啉磺酰氯的制备方法
JP7692834B2 (ja) 2019-03-11 2025-06-16 ノシオン セラピューティクス,インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US10786485B1 (en) 2019-03-11 2020-09-29 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
BR112021017809A2 (pt) 2019-03-11 2021-11-23 Nocion Therapeutics Inc Bloqueadores de canais iônicos substituídos por éster e métodos para uso
BR112021017772A2 (pt) 2019-03-11 2021-11-16 Nocion Therapeutics Inc Bloqueadores de canais de íons carregados e métodos para uso
AU2020380118A1 (en) 2019-11-06 2022-05-19 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP7513713B2 (ja) 2019-11-06 2024-07-09 ノシオン セラピューティクス,インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
BR112022017801A2 (pt) 2020-03-11 2022-10-25 Nocion Therapeutics Inc Bloqueadores de canais de íons carregados e métodos para uso
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
AU2022270061A1 (en) * 2021-05-07 2023-11-16 Merck Sharp & Dohme Llc Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
CN115015310B (zh) * 2022-05-23 2024-12-10 宁波大学 一种巯基化合物的分析方法
KR20240172702A (ko) * 2023-05-30 2024-12-10 삼진제약주식회사 신규한 벤즈아미드 유도체 화합물 및 이를 포함하는 약학적 조성물
WO2025137437A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Solid forms of a gabaa receptor modulator and methods of its use

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514696A (en) 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US6673824B1 (en) 1992-05-06 2004-01-06 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5786373A (en) 1992-10-14 1998-07-28 Merck & Co., Inc. Fibrinogen receptor antagonists
US5688830A (en) 1996-01-25 1997-11-18 Syntex (U.S.A.) Inc. Treatment of neuropathic pain
JP2000511883A (ja) 1996-04-19 2000-09-12 ノボ ノルディスク アクティーゼルスカブ ホスホチロシン認識ユニットを有する分子のモジュレーター
DE69719766T2 (de) 1996-08-29 2004-01-15 Takeda Chemical Industries Ltd Zyklische etherverbindungen als natriumkanal-modulatoren
ID25921A (id) 1997-04-28 2000-11-09 Texas Biotechnology Corp Sulfonamida-sulfonamida untuk pengobatan penyakit-penyakit yang dimediakan endotelin
GB9800750D0 (en) * 1998-01-14 1998-03-11 Lilly Co Eli Pharmaceutical compound
GB9805520D0 (en) 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
US6586475B1 (en) 1998-11-20 2003-07-01 Takeda Chemical Industries, Ltd. β-amyloid protein production/secretion inhibitors
WO2000053573A1 (en) 1999-03-10 2000-09-14 Shionogi & Co., Ltd. Medicinal compositions with [2.2.1] and [3.1.1] bicycloskeleton antagonistic to both of pgd2/txa2 receptors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6495550B2 (en) 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
WO2001016094A1 (de) 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2001049289A1 (en) 1999-12-31 2001-07-12 Texas Biotechnology Corporation Pharmaceutical and veterinary uses of endothelin antagonists
IL150311A0 (en) 1999-12-31 2002-12-01 Texas Biotechnology Corp Sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2001070734A2 (en) 2000-03-17 2001-09-27 Bristol-Myers Squibb Pharma Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
US20040110743A1 (en) 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001270029A1 (en) 2000-06-21 2002-01-02 Smith Kline Beecham Corporation Macrophage scavenger receptor antagonists
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
CA2466490C (en) 2001-11-22 2009-12-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA04004837A (es) 2001-11-22 2004-08-02 Biovitrum Ab Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
JP2003292485A (ja) * 2002-04-01 2003-10-15 Yamanouchi Pharmaceut Co Ltd スルホンアミド誘導体
AU2003226929A1 (en) 2002-11-25 2004-06-18 7Tm Pharma A/S Novel benzamide compounds for use in mch receptor related disorders
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
BRPI0409949A (pt) 2003-05-01 2006-04-25 Bristol Myers Squibb Co compostos de pirazol amida aril-substituìda úteis como inibidores de cinase
FR2856133B1 (fr) 2003-06-16 2005-11-04 Commissariat Energie Atomique Dispositif d'exploration de canalisations avec tete centree
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
SE0301886D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use V
SE0301888D0 (sv) 2003-06-25 2003-06-25 Biovitrum Ab New use VII
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7538135B2 (en) 2003-07-08 2009-05-26 Novartis Ag Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
TW200524888A (en) 2003-08-08 2005-08-01 Vertex Pharma Compositions useful as inhibitors of voltage-gated ion channels
US20070191336A1 (en) 2003-12-24 2007-08-16 Flynn Daniel L Anti-inflammatory medicaments
WO2006060762A2 (en) 2004-12-03 2006-06-08 Arena Pharmaceuticals, Inc. Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
JP2009514858A (ja) 2005-11-03 2009-04-09 メルク エンド カムパニー インコーポレーテッド アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤
AU2007238897A1 (en) 2006-04-12 2007-10-25 Wyeth Anilino-pyrimidine phenyl and benzothiophene analogs

Similar Documents

Publication Publication Date Title
JP2010522242A5 (enExample)
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
NO20090095L (no) Anvendelse av en hydrofil matriks omfattende et polyakrylsyrederivat, en cellulose-eter og et disintegreringsmiddel for fremstilling av et medikament for behandling av kvinners genitale forstyrrelser
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
EP2444072A3 (en) Non-mucoadhesive film dosage forms
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
JP2016147915A5 (enExample)
JP2013231087A5 (enExample)
IL215826A (en) Pharmaceutical preparation with delayed release, process of preparation of the preparation, use of the preparation for the preparation of pain medication and the pill containing it.
JP2013541583A5 (enExample)
JP2017105861A5 (enExample)
JP2014526559A5 (enExample)
JP2019089796A5 (enExample)
JP2013166781A5 (enExample)
JP2012508256A5 (enExample)
JP2010500284A5 (enExample)
JP2011500589A5 (enExample)
FR2918282B1 (fr) Medicament pour le traitement de la maladie de parkinson
UA111480C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
JP2010519192A5 (enExample)
JP2012525422A5 (enExample)